PRINCETON, N.J.–(BUSINESS WIRE)–#Hydroxychloroquine–Sun Pharmaceutical Industries, Inc., USA, (SPII),a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (‘together Sun Pharma,’ Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715), announced that it has donated 2.5 million hydroxychloroquine sulfate tablets for use in the United States. Sun Pharma is seeking to enable health care experts meet the growing patient demands for this product as they assess its potential to treat COVID-19 through clinical trials.
“At Sun Pharma, we are resolute in our purpose to help people live healthier lives and stand united in our global fight against COVID-19,” said Abhay Gandhi, CEO, Sun Pharma, North America. “We are working with supply chain partners and wholesalers to help ensure swift delivery to areas where it will provide the most benefit as the clinical trials progress.”
Hydroxychloroquine sulfate tablets manufactured by Sun Pharma are approved by the U.S. Food and Drug Administration (FDA) for the treatment of a range of conditions including malaria, lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is not currently approved for use in the treatment of COVID-19; however, it is currently under investigation as a possible treatment option for coronavirus.
Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.
About Sun Pharmaceutical Industries Ltd. (CIN – L24230GJ1993PLC019050):
Sun Pharmaceutical Industries Inc., USA is a wholly owned subsidiary of Sun Pharma, world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 7% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma_Live
Email: [email protected]
Email: [email protected]